BriaCell Therapeutics Corp. announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer, effective February 16, 2022. Dr. Del Priore will oversee the clinical and regulatory aspects of BriaCell's current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT, with Incyte's checkpoint inhibitors, retifanlimab and epacadostat in advanced breast cancer.